181 related articles for article (PubMed ID: 23294331)
1. Light chain amyloidosis 2012: a new era.
Gatt ME; Palladini G
Br J Haematol; 2013 Mar; 160(5):582-98. PubMed ID: 23294331
[TBL] [Abstract][Full Text] [Related]
2. [Current treatment of AL amyloidosis].
Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A
Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
4. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
Gertz MA; Dispenzieri A
Oncology (Williston Park); 2012 Feb; 26(2):152-61. PubMed ID: 22489348
[TBL] [Abstract][Full Text] [Related]
7. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
[TBL] [Abstract][Full Text] [Related]
9. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
[TBL] [Abstract][Full Text] [Related]
10. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
[TBL] [Abstract][Full Text] [Related]
12. Light-chain amyloidosis: SCT, novel agents and beyond.
Rosenzweig M; Giralt S; Landau H
Bone Marrow Transplant; 2013 Aug; 48(8):1022-7. PubMed ID: 23103675
[TBL] [Abstract][Full Text] [Related]
13. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
[TBL] [Abstract][Full Text] [Related]
15. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Sher T; Hayman SR; Gertz MA
Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
Gertz MA
Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
[TBL] [Abstract][Full Text] [Related]
18. Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy.
Scully MS; Wessman DE; McKee JM; Francisco GM; Nayak KR; Kobashigawa JA
Mil Med; 2017 Mar; 182(3):e1858-e1860. PubMed ID: 28290973
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
20. [Amyloid light chain amyloidosis].
Suzuki K; Shimizu T
Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
